Bystryn, J. Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine
prepared from shed antigens. Ann NY Acad Sci, 1993, 690: 190-201.
Berd, D; Maguire, HC; and Mastrangelo, MJ. Treatment of human melanoma with a
hapten-modified autologous vaccine. Ann NY Acad Sci, 1993, 690: 147-52.
Chen, PW; Geer, DC; Podack, ER; and Ksander, BR. Tumor Cells Transfected with B7-1 and
Interleukin-12 cDNA Induce Protective Immunity. Ann NY Acad Sci, 1996, 795: 325-7.
Dalgleish, AG. Cancer vaccines. Eur J Cancer, 1994, 30A: 1029-1035.
Dorr, RT and Von Hoff, DD. The Cancer Chemotherapy Handbook, Second Ed. Appleton
and Lange, 1994, 227-36.
Durrant, LG and Spendlove, I. Cancer vaccines. QJ Med, 1996, 89: 645-51.
Finn, OJ; Jerome, KR; Henderson, RA; Pecher, G; Domenech, N; Magarian-Blander, J; and
Barratt-Boyes, SM. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Imm
Rev, 1995, 145: 62-83.
Hanna, MG; Ransom, JH; Pomato, N; and Peters, L. Active specific immunotherapy of human
colorectal carcinoma with an autologous tumor cell. Ann NY Acad Sci, 1993, 690: 135-46.
Hellstrom, KE; Hellstrom, I; Linsley, P; and Chen, L. On the Role of Costimulation in
Tumor Immunity. Ann NY Acad Sci, 1993, 690: 225-30.
Herlyn, D; Somasundaram, R; Li, W; and Maruyama, H. Anti-idiotype cancer vaccines:past and
future. Cancer Immunol Immunother, 1996, 43: 65-76.
Hilleman, MR. The promise and the reality of viral vaccines against cancer. Ann NY Acad
Sci, 1993, 690: 6-23.
Houghton, AN. On course for a cancer vaccine. Lancet, 1995, 345 (8962): 1384-85.
Koeppen, H; Singh, S; and Schreiber, H. Genetically engineered vaccines: comparison of
active versus passive immunotherapy against solid tumors. Ann NY Acad, 1993, Sci 690:
244-55.
Livingston, PO. Approaches to augmenting the IgG antibody response to melanoma ganglioside
vaccines. Ann NY Acad Sci, 1993, 690: 204-9.
Livingston, PO. Approaches to augmenting the immunogenicity of melanoma gangiosides: from
whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev, 1995, 145:
147-66.
Magarian-Blander, J; Domenech, N; and Finn, OJ. Specific and Effective T-Cell Recognition
of Cells Transfected with a Truncated Human Mucin cDNA. Ann NY Acad Sci, 1993, 690:
231-43.
Mitchell, MS; Harel, W; Kan-Mitchell, J; LeMay, L; Goedegebure, P; Huang, X; Hofman, F;
and Groshen, S. Active specific immunity of melanoma with allogeneic cell lysates. Ann NY
Acad Sci, 1993, 690: 153-66.
Morton D, Hoon D, Nizze JA, Foshag LG, Famatiga E, Wanek LA, Chang C, Irie RF, Gupta RK,
and Elashoff R. Polyvalent melanoma vaccine improves survival of patients with metastatic
melanoma. Ann NY Acad Sci, 1993, 690: 120-34.
Nelson NJ. Cancer vaccines, disappointing in the past, show promise. J Natl Cancer Inst,
1993, 88: 486-488.
Old LJ. Immunotherapy for Cancer. Scientific American, Sept. 1996, 136-43.
Pardoll DM. Genetically Engineered Tumor Vaccines. Ann NY Acad Sci, 1993, 690: 301-10.
Porth CM. Pathophysiology: Concepts of Altered Health States, Second Ed. J.B.
Lippincott, 1986, pp. 77-8.
Putnam D and Kopecek J. Polymer conjugates with anticancer activity. Advances in Polymer
Science, 1995, 122: 55-124.
Schmidt W, Schweighoffer T, Herbst E, et al. Cancer vaccines: the interleukin 2 dosage
effect. Proc Natl Acad Sci, 1995, 92: 4711-14.
Schmidt W, Steinlein P, Buschle M, et al. Transloading of tumor cells with foreign major
histocompatibility complex class I peptide ligand: a novel general strategy for the
generation of potent cancer vaccines. Proc Natl Acad Sci, 1996, 93: 9759-63.
Service RJ. An Immune Boost to the War on Cancer. Science, 1996, 272: 28-30.
Sherwood L. Human Physiology: From Cells to Systems, Second Ed. West Publishing
Co., 1993, pp. 399-400.
Skolnick AA. Essential components now in place for clinical testing of cancer vaccine
strategies. JAMA, Feb. 15, 1995, 273 (7), 528-30.
Sogn JA, Finerty JF, Heath AK, Shen GL, and Austin FC. Cancer vaccines: the perspective of
the cancer immunology branch, NCI. Ann NY Acad Sci, 1993, 690: 322-29.
Viewig J, Gilboa E. Considerations for the use of cytokine-secreting tumor cell
preparations for cancer treatment. Cancer Investigation, 1995, 13(2), 193-201.
Wallak MK, Sivandham M. Clinical trials with VMO for melanoma. Ann NY Acad Sci, 1993, 690:
178-89.
Back to Home